StreetInsider.com News Articles

William Blair Reiterates Market Perform Rating on Neogen (NEOG) amid genomics business sale

Mon, 02 Mar 2026 15:15:19 -0500

William Blair analyst Brandon Vazquez reiterated a Market Perform rating on Neogen (NASDAQ: NEOG)

The analyst commented, "For Neogen, we believe this deal is positive as the company continues to execute on its communicated initiatives, at what we consider a good price. As the company continues to dissect animal health, we believe this will help the business on an operating front and also alleviate some of the pressures the company has been facing in terms of other P&L concerns (especially debt leverage ratio and EBITDA margin expansion). For context, this segment generated about $90 million in revenues in 2025, with EBITDA

Neogen to sell genomics business to Zoetis for $160 million

Mon, 02 Mar 2026 07:01:05 -0500

Neogen Corporation (NASDAQ: NEOG) announced it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. for $160 million, subject to customary closing adjustments.

The transaction is expected to close by the end of the first half of Neogen's 2027 fiscal year, pending regulatory approval and customary closing conditions. The genomics business generated approximately $90 million in sales during fiscal year 2025.

Neogen plans to use the net proceeds primarily for debt reduction. The divestiture is part of the company's portfolio review strategy to focus on core strategic markets.

"This transaction is part of the company's strategic portfolio

Neogen to sell genomics business to Zoetis for $160 million

Mon, 02 Mar 2026 07:01:05 -0500

Neogen Corporation (NASDAQ: NEOG) announced it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. for $160 million, subject to customary closing adjustments.

Neogen plans to use the net proceeds primarily for debt reduction. The divestiture is part of the company's portfolio review strategy to focus on core strategic markets.

"This transaction is part of the company's strategic portfolio

Neogen to sell genomics business to Zoetis for $160 million

Mon, 02 Mar 2026 07:01:05 -0500

Neogen Corporation (NASDAQ: NEOG) announced it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. for $160 million, subject to customary closing adjustments.

Neogen plans to use the net proceeds primarily for debt reduction. The divestiture is part of the company's portfolio review strategy to focus on core strategic markets.

"This transaction is part of the company's strategic portfolio

Neogen to sell genomics business to Zoetis for $160 million

Mon, 02 Mar 2026 07:01:05 -0500

Neogen Corporation (NASDAQ: NEOG) announced it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. for $160 million, subject to customary closing adjustments.

Neogen plans to use the net proceeds primarily for debt reduction. The divestiture is part of the company's portfolio review strategy to focus on core strategic markets.

"This transaction is part of the company's strategic portfolio

Zoetis to acquire Neogen's animal genomics unit for $160 million

Mon, 02 Mar 2026 07:00:20 -0500

Zoetis Inc. (NYSE: ZTS) announced it has entered into a definitive agreement to acquire Neogen Corporation's (NASDAQ: NEOG) animal genomics business for $160 million, subject to customary closing adjustments.

The acquisition includes Neogen's genomics operations that serve customers in more than 120 countries through five laboratories in the United States, Brazil, Australia, China and the United Kingdom, plus an office in Canada. The business uses genotyping platforms and sequencing technologies along with software solutions for genetic testing and analysis.

Neogen's genomics division operates in U.S. beef and dairy genomics markets and provides genetic testing services for livestock and companion animals. The unit

Zoetis to acquire Neogen's animal genomics unit for $160 million

Mon, 02 Mar 2026 07:00:20 -0500

Neogen's genomics division operates in U.S. beef and dairy genomics markets and provides genetic testing services for livestock and companion animals. The unit

Zoetis to acquire Neogen's animal genomics unit for $160 million

Mon, 02 Mar 2026 07:00:20 -0500

Neogen's genomics division operates in U.S. beef and dairy genomics markets and provides genetic testing services for livestock and companion animals. The unit

Zoetis to acquire Neogen's animal genomics unit for $160 million

Mon, 02 Mar 2026 07:00:20 -0500

Neogen's genomics division operates in U.S. beef and dairy genomics markets and provides genetic testing services for livestock and companion animals. The unit

Zoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health Innovation